Invesco Biotechnology & Genome ETF Rating $67.86 +0.28 (+0.41%) Closing price 08/26/2025 04:10 PM EasternExtended Trading$67.86 +0.00 (+0.01%) As of 08/26/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy 2.71Holdings in PBE have an aggregate rating of Moderate Buy based on 348 analyst ratings issued in the past year covering 25 companies (91.8% of the portfolio).PBE Aggregate Price Target$67.86High Prediction$67.86Average Prediction$67.86Low Prediction$67.86Holdings in PBE have an aggregate price target of $67.86 and a range of $67.86 to $67.86 covering 25 companies (91.8% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy6 Buy rating(s)Moderate Buy14 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 PBE Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.46%ALNYAlnylam Pharmaceuticals$451.20+1.7%4.0351 of 5 stars2.85$405.33 -10.2%265.76%ILMNIllumina$98.73-0.9%4.8663 of 5 stars2.25$124.58 26.2%20Positive News5.63%RPRXRoyalty Pharma$35.980.0%4.9807 of 5 stars3.33$48.00 33.4%3News CoveragePositive News5.09%BMRNBioMarin Pharmaceutical$57.45-1.8%4.9955 of 5 stars2.72$93.17 62.2%25Positive News5.07%AMGNAmgen$289.58+0.4%4.7396 of 5 stars2.33$304.43 5.1%21Trending NewsAnalyst Forecast5.03%GILDGilead Sciences$114.75+0.5%4.9837 of 5 stars2.88$115.39 0.6%26Positive News4.73%UTHRUnited Therapeutics$309.22+1.3%4.9251 of 5 stars2.69$382.00 23.5%13Positive NewsAnalyst Revision4.19%VRTXVertex Pharmaceuticals$387.18-0.5%4.9576 of 5 stars2.56$497.10 28.4%27Positive News4.13%AVXLAnavex Life Sciences$9.53+1.4%3.734 of 5 stars3.00$44.00 361.7%23.25%INCYIncyte$84.00-0.9%4.6615 of 5 stars2.33$81.60 -2.9%183.10%HALOHalozyme Therapeutics$72.93+1.0%4.6404 of 5 stars2.18$67.11 -8.0%11Positive News3.07%DVAXDynavax Technologies$10.44+0.5%4.6277 of 5 stars2.50$24.33 133.1%4Positive News3.03%COLLCollegium Pharmaceutical$38.58-0.5%2.1576 of 5 stars3.00$42.33 9.7%3Positive News2.99%QGENQiagen$48.890.0%3.7712 of 5 stars2.27$49.69 1.6%11News CoveragePositive News2.98%ACADACADIA Pharmaceuticals$25.72+1.6%3.8936 of 5 stars2.61$28.88 12.3%18Positive News2.98%PTGXProtagonist Therapeutics$56.99+0.2%1.9135 of 5 stars3.00$67.20 17.9%9News CoveragePositive News2.95%FOLDAmicus Therapeutics$7.52+0.5%4.3223 of 5 stars2.80$16.22 115.7%10Positive News2.85%PTCTPTC Therapeutics$49.46+0.3%4.3369 of 5 stars2.63$69.15 39.8%162.83%ARWRArrowhead Pharmaceuticals$21.18+2.3%3.7543 of 5 stars3.00$43.14 103.7%9News CoveragePositive News2.78%NBIXNeurocrine Biosciences$136.84+2.1%4.8596 of 5 stars2.86$159.50 16.6%21Positive News2.68%VCYTVeracyte$29.07-1.6%2.4194 of 5 stars2.70$40.90 40.7%10Positive NewsGap Up2.51%RGENRepligen$120.49-0.6%4.8549 of 5 stars2.73$169.45 40.6%11Positive News2.35%EXELExelixis$38.34+1.2%4.878 of 5 stars2.55$44.06 14.9%222.21%MNKDMannKind$4.07+4.4%3.2911 of 5 stars3.25$9.86 142.2%8Trending NewsAnalyst ForecastGap Up2.15%TGTXTG Therapeutics$28.28-0.9%4.4119 of 5 stars2.75$46.25 63.5%4Positive News This page (NYSEARCA:PBE) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access